1

CURRICULUM VITAE

MARGARET E. WIERMAN, M.D.

Business Address: University of Colorado School of Medicine Division of Endocrinology, Metabolism and Diabetes, Mail Stop 8106 RC1 S, Room 7103 12801 E. 17th Ave. PO Box 6511 Aurora, CO 80045 303-724-3952 Fax: 303-724-3920 Email margaret.wierman@ucdenver.edu

Education:

Veterans Affairs Medical Center Chief, Section of Endocrinology (111H) 1055 Clermont Street Denver, CO 80220 (303) 399-8020 x 3150 Fax: (303) 393-5271

1971-1975 B.A. - Bryn Mawr College, Bryn Mawr, PA 1979 M.D. - Baylor College of Medicine, Houston, TX

Postdoctoral Training: Internship and Residencies: 1979-1982 Resident in Internal Medicine, Baylor College of Medicine 1982 Chief Medical Resident, Houston Veterans Administration Medical Center, Baylor College of

Medicine Fellowships: 1983-1987 Research Fellow in Medicine, Harvard Medical School 1983-1987 Clinical Fellow in Medicine, Massachusetts General Hospital 1983-1987 Clinical and Research Fellow in Reproductive Endocrinology, Massachusetts General

Hospital 1983-1987 Clinical and Research Fellow in Gynecology, Massachusetts General Hospital 1985-1987 Research Fellow in Medicine, Brigham and Women's Hospital

Academic Appointments: 1982-1983 Instructor in Internal Medicine, Baylor College of Medicine 1983-1987 Research Fellow in Medicine, Harvard Medical School 1983-1987 Associate Staff in Medicine, Massachusetts Eye and Ear Infirmary 1987-1987 Instructor in Medicine, Harvard Medical School 1987-1993 Assistant Professor in Medicine, University of Colorado School of Medicine 1993-2001 Associate Professor in Medicine, University of Colorado School of Medicine 1997-Pres. Chief, Section of Endocrinology, Denver Veterans Affairs Medical Center 1999-2001 Associate Professor in Physiology and Biophysics, University of Colorado School of

Medicine

2

1998-Pres. Member, Biomedical Sciences Graduate Program, University of Colorado School of Medicine

2001-Pres. Professor in Medicine, Physiology and Biophysics, University of Colorado School of Medicine

2001-Pres Member of Neuroscience graduate training program, University of Colorado School of Medicine

2004-Pres Member of Program in Reproductive Sciences training program, University of Colorado School of Medicine

2009-Pres Director, University of Colorado Pituitary Program 2014-Pres Professor, Obstetrics and Gynecology, University of Colorado School of Medicine

Licensure and Certification: 1979-1994 Texas State Board of Medical Examiners 1983-1988 Massachusetts Board of Medical Examiners 1982 American Board of Internal Medicine 1985 Subspecialty - Endocrinology and Metabolism 1987 Colorado Board of Medical Examiners

Honors: 1979 Baylor Medical Alumni Outstanding Student Award 1988-1992 Research Associate Award, Veterans Affairs 1995-1999 Clinical Investigator Award, Veterans Affairs 1997 American Society of Clinical Investigation 2009 Sidney Ingbar Award for Distinguished Service, The Endocrine Society 2012-2015 Vice President Clinical Scientist, The Endocrine Society 2015 University of Colorado Health Presidents Citation for Meritorious Service 2015 Women in Endocrinology Mentor Award 2015 Endocrinology Division UCSOM Mentor Award inaugural year

Associations and Societies: 1986- The Endocrine Society 1986- American Federation of Clinical Research 1987- Women in Endocrinology 1993- Western Society for Clinical Investigation 1995- Society for Neuroscience 1995- American Neuroendocrine Society 1997- American Society of Clinical Investigation

Teaching Experience: 1976 Teaching Assistant, Anatomy and Cell Biology, Baylor College of Medicine 1982 Teaching Responsibilities as Chief, Medical Resident: Morning report, Medical Service

conferences, Rounding with General Medicine Teams, Student conferences 1983 Pelvic Examination Instructor, Harvard Medical School 1984-1987 Lecturer, Reproductive Endocrinology Post-graduate course, Harvard Medical School 1987- Lecturer, Endocrine Pathophysiology Course, University of Colorado Medical School 1988-1993 Lecturer, Patient Problems at the Root of Science for first year medical students 1988- Resident Housestaff Conferences "Amenorrhea, Hypothalamic-Pituitary Disorders" 1988- Clinical Laboratory Course for 4th year medical student lecture on evaluation of male and

female reproductive axis 1990-2000 Internal Medicine Review Course 1990-2009 UC Cancer Center summer student lecture on Breast Cancer: a hormone dependent

malignancy 1991-1995 Coordinator of Endocrine Pathophysiology, University of Colorado Medical School

3

1991-1993 Cancer Center Sponsored Community Lectures on "Hormone Replacement in the Menopause"

1992-1993 Lecturer on Endocrine system at the Mini-Medical School at UCD 1993-2007 Clinical correlation on "The Menopause" in Physiology for first year medical students 1997-2006 Molecular and Cellular Physiology: Molecular Endocrinology “New Insights Into the

Physiology of the Reproductive Axis” 1999- Gonadal Physiology lecture to first year endocrine fellows, UCD 2005- RPSC780 Endocrine Physiology: Kallmann Syndrome and Precocious Puberty: 1h

IDPT Tissues and disease: Reproductive disorders: 3h 2006-2008 PHCL7606 Signaling course: lectures on steroid receptor signaling 3h 2007 Design of the Reproductive Endocrine lectures and workshops for the Lifecycles

component of the revised medical school curriculum 8h 2008- Lecturer Life Cycles: male and female reproductive physiology and workshops 4.5-6h 2009-2014 IDPT Tissues and Diseases, lectures on the Male and Female reproductive axis and

infertility, 3h 2010-2011 Facilitator for CTSA Mentoring Trial UCD site (cofacilitated mentoring training research

protocol 5-2hr sessions) 2010- Initiated and coordinate Pituitary Patient Day educational course for patients and family 6h

yearly 2012- Neuroscience graduate program core course: Hypothalamus and Pituitary lecture and

journal club 8hr 2012- VA SCAN ECHO lectures on diabetes and endocrine topics to our VISN and nationally 2012- Endocrine Society Board Review, creation of section on female reproduction for national

meeting, questions and lectures Principal Clinical and Hospital Service Responsibilities: 1983-1987 Reproductive Endocrinology Clinic, Massachusetts General Hospital 1983-1987 Staff in Medicine, Massachusetts Eye and Ear Infirmary 1987- Staff Physician, Veterans Affairs Medical Center, Denver, CO 1987- Staff Attending - Endocrine Consult Service, University Hospital, Aurora, CO 1999- Chief of Endocrinology, Denver VA Medical Center 2009- Director, University of Colorado School of Medicine Pituitary and Adrenal Program

Committees: 1989-1993 Scientific Protocol Review Committee, VAMC 1990-1993 Chairman, Molecular Core Committee, VAMC 1990-1993 Biohazards and Biosafety Committee, VAMC 1991-1993 Chairman, Biohazards and Biosafety Committee, VAMC 1990-1993 Research & Development Committee, VAMC 1990-1993 Women in Academic Medicine, UCHSC 1990- Cancer Center Member 1991-2007 Clinical Research Center Scientific Advisory Committee, UCD 1994-1997 Women in Endocrinology Nominating Committee 1995-2000 Faculty Senate, UCHSC 1995-1998 Organizing Committee for the American Neuroendocrine Society 1996-1997 Women in Endocrinology, Chair Nominating Committee 1996-1999 The Endocrine Society Annual Meeting Steering Committee 1996-2000 Western Society Clinical Investigation (WSCI) Council 1997-2000 WSCI Secretary/Treasurer 1997-2001 Student Awards & Research Committee, UCD 1998-1999 Chair, Annual Meeting Steering Committee of the Endocrine Society 1998-2001 Meetings and Educational Programs Committee, The Endocrine Society 1999-2002 Chair, Meetings and Educational Programs Committee, The Endocrine Society

4

1999-2000 President Elect, Women in Endocrinology 2000-2001 Clinical Affairs Committee of Faculty Senate, UCD 2000-2002 President, Women in Endocrinology 2001-2002 President, Western Society of Clinical Investigation 2002-2005 Medical Research Advisory Group, Veterans Affairs 2003-2004 Emerging Leaders Program, UCD 2003-2005 Research Affairs, Council liaison, The Endocrine Society 2002-2005 Councilor at Large, The Endocrine Society 2003-2006 SIRC, Strategic Initiatives Research Committee to the Dean, UCD 2003- Planning and oversight committee for Program in Reproductive Science (PiRS), UCD 2003- Professor Promotions Committee, Dept. Medicine, UCD 2003-2007 Federal Drug Administration: Endocrinologic and Metabolic Drugs Advisory Panel 2004-2007 GCRC Advisory Committee (GAC), University of Colorado 2005-2007 Finance Committee, The Endocrine Society 2005-2006 Chair, Strategic Initiatives Research Committee to the Dean, UCD 2005-2006 Chair, The Endocrine Society Guidelines Committee on Therapeutic use of Androgens in

Women 2006- Training faculty for UCD WHRHR 2007- Training faculty for UCD BIRCWH 2007-2010 Nominating Committee, The Endocrine Society 2008-2012 PCIR advisory committee to the CTSA, UCD 2009-2010 LiTES program in leadership development, CTSA, UCD 2009-2010 Chair, The Nominating Committee, The Endocrine Society 2010-2014 Awards Committee, The Endocrine Society, Chair 2012-2013 2010-2013 Research Advisory Committee (RAC) to the Dean, UCD, Chair 2012-2013 2011-2013 Endocrine Society Task Force on Truth in Hormone Assays 2011-2013 CoChair Endocrine Society Annual Meeting Template Task Force 2012-2014 Chair, Endocrine Society Guidelines Committee revisit of Therapeutic use of Androgens in

Women 2013-2014 Chair, Clinical Scientist Task Force Survey, the Endocrine Society 2014-2015 Chair, Sex Steroid Reporting Task Force, the Endocrine Society 2014-2015 Next Generation Task Force, the Endocrine Society 2014-2015 Needs Assessment Working Group, the Endocrine Society 2015-2016 Chair, Bench to Bedside, Keys to Succeeding in Translational Science, the Endocrine

Society Reviewer: 1989- Ad hoc reviewer for Merit Review and Career Development applications for the Veterans

Affairs 1990- Ad hoc reviewer for Endocrinology, Molecular Endocrinology, Biology of Reproduction 1991-2006 Ad hoc reviewer for National Science Foundation applications 1994-1997 Editorial Board, Journal of Clinical Endocrinology and Metabolism 1995 Site Review Member for Center in Reproductive Medicine 1997-2007 Reviewer, JAMA WEB 1998- U54 Centers for Reproductive Research, NICHD Site Review Committee Member 1998-2002 Population Research Subcommittee, NICHD Study Section 1999- Editorial Board, Neuroendocrinology 2000-2002 Chair, Population Research Subcommittee, NICHD Study Section 2000-2004 Veterans Affairs Career Development Review Panel 2003-2004 Reproductive Endocrinology Study Section, NIH 2004-2005 Chair, Review of Specialized Programs in Reproduction, NICHD 2004-2007 Integrative Clinical Endocrinology and Reproduction Study Section (ICER),NIH

5

2005-2007 Chair, ICER Study Section (NIH) 2007,2008 U54 Infertility Centers Review Panel 2009 External review of NICHD SCCPR program 2010-2015 Associate Editor, Endocrine Reviews 2011-2014 Editorial board, Endocrine 2011- Ad hoc reviewer JCEM, Endocrinology, Molecular Endocrinology, BMJ 2014-2015 Acting Editor, Endocrine Reviews

Graduate Comprehensive Exam/Thesis Committees: 1999-2003 Kina Thackeray, Molecular Biology Program, UCD 2001-2005 Melanie Gubbels, Medical Genetics, UCD 2007-2011 Faye Doherty, Neuroscience, UCD (chair of thesis defense committee) 2013-2014 Emily Busta, Reproductive Sciences UCSOM (thesis committee member) 2014- Allison Booth, Reproductive Sciences UCSOM (chair, comprehensive exam committee)

Consultant 2007- National Hockey League for hormonal disorders 2008- LPGA for hormonal disorders 2014- USADA US anti-doping agency

Invited Lectures: 1990 MGH Basic Science Research Series 1991 Serono Symposia on GnRH and its Analogues 1991 Visiting Lecturer, Department of Neurobiology and Physiology, Northwestern University 1992 The Endocrine Society Postgraduate Assembly 1992 Visiting Lecturer, Tufts University Center for Reproductive Research 1992 Reproductive Endocrine Unit, MGH Seminar Series 1994 Colorado Diabetes/Endocrine Institute, Snowmass, Colorado 1994 International Symposium on Puberty, National Academy of Medicine, Buenos Aires,

Argentina 1994 Fourth International Conference on The Control of the Onset of Puberty, Pittsburgh,

Pennsylvania 1995 Society for the Study of Reproduction, Plenary Lecturer “Control of GnRH Gene

Expression” 1995 American College of Rheumatology, Plenary Lecturer, Women's Health “Estrogens and

Systemic Lupus Erythematosis” 1997 Reproductive Endocrine Unit, MGH, Basic Science Seminar Series 1998 Controversies in Colorado Women’s Health: “Risks and Benefits of HRT”, A Working

Symposium, Colorado Women’s Health Campaign 1998 Coordinator of Symposia on “Frontiers in the Science of Estrogen Action”, April 1998,

Denver, CO 1998 17th Annual Day of Caring “Hormone Replacement Therapy vs. SERMs in Breast Cancer

Survivors”, May 1998 1998 Visiting Professor, Medical College of Georgia, Department of Physiology “Novel Factors

Controlling GnRH Expression and Neuronal Migration” 1998 American Society of Bone and Mineral Research, San Francisco, “SERMs and the Aging

Cell” 1999 Clinical Diabetes and Endocrinology in 1999, Snowmass, CO “SERMs: New Tissue

Specific Estrogen Analogs” and “New Insights into Erectile Dysfunction and Hypogonadism”

1999 Molecular, Cellular and Developmental Biology, UC Boulder Seminar Series “Novel Factors Controlling GnRH Neuronal Development: Role of Ark”

1999 Reproductive Seminar Series, University of Virginia, “Regulation of GnRH expression”

6

1999 5th International Congress on the Control of Puberty, Liege, Belgium, “Developmental control of GnRH gene expression: Role of POU proteins”

1999 Visiting Professor, Wayne State University, Division of Endocrinology, “Developmental Control of GnRH by POU proteins”

1999 Geriatrics Grand Rounds, UCD, “Glucocorticoid induced osteoporosis” 2000 Invited Participant, Sex and Gene Expression, Institute on Women’s Health, West Virginia 2000 Experimental Biology 2000, FASEB, “Symposia on the Cell Biology of the GnRH Neuron” 2000 Visiting Professor, Reproductive Biology, UCSD, “Role of Adhesion related kinase in

GnRH neuronal migration and survival” 2000 The Endocrine Society, Toronto, CA, Invited Symposium, “Factors that Control GnRH” 2000 Neuroendocrinology 2000, Satellite Symposia of ICE, Australia, “Developmental Control of

GnRH” 2000 International Congress in Endocrinology, Sydney Australia, “Novel Factors that Control

GnRH Neuronal Migration and Gene Expression” 2001 Western Society for Clinical Investigation, State of the Art speaker in Endocrinology 2001 Leonard Lectureship, University of Washington School of Medicine, “SERMs: Basic

Insights and Clinical Applications” 2002 Comparative Endocrinology, Annual National Veterenary Medical Conference, Denver,

CO, “Adrenal physiology” 2001 The University of Texas, San Antonio, Endocrine Grand Rounds, “Androgens in Women:

too much, too little, just right” 2003 Ashland Endocrine Conference, Ashland Oregon “Beyond the WHI: Estrogens and

Alternatives” 2003 Molecular, Cellular and Integrative Neurosciences Seminar Series, CSU, Fort Collins, CO,

“Control of the GnRH Neuron” 2003 Development of the Neuroendocrine Axis, University of Massachusetts, Amherst, MA,

“Signaling Pathways for GnRH Neuronal Migration” 2004 Clinical Endocrinology & Diabetes, Snowmass Meeting, Snowmass, CO: “Testosterone in

Men, Too Much, Too Little Just right”, “Update on the Diagnosis and Treatment of PCOS”. 2004 Osborne Lecture, Molecular Mechanisms of Reproductive Development, Reproductive

Sciences, Kansas University Medical School, Kansas City, Kansas 2005 Clinical Endocrinology and Diabetes, Snowmass Meeting, Snowmass, CO: “Androgens in

Women: what are the data? ” and “After WHI: is Estrogen Out?” 2005 Research Day Dept of Medicine UCDHSC, “Identification of Novel Factors involved in

pituitary tumorigenesis” 2005 NICHD Symposia on the GnRH Neuron, keynote lecture, “GnRH neuron biology: through

the looking glass” 2006 The University of Texas, San Antonio, Endocrine Grand Rounds, “The role of androgens in

women” 2006 American Physiologic Society, San Francisco, CA, “Sex Steroid Action in Target Tissues:

mechanism of action” 2006 Women’s Health Colorado Research Symposium, Aurora, CO – “Emerging Issues in

Women’s Health. After the WHI: Estrogen- Yes or No?” 2007 Visiting Professor University of Texas Southwestern Dept OBGYN, “Role of chemokine

receptors in GnRH neuron biology” 2007 Massachusetts General Hospital, Harvard Endocrine Grand Rounds, “Role of Axl tyrosine

kinase receptors in GnRH neuron biology” 2008 Clinical Endocrinology and Diabetes Meeting, Snowmass CO: “PCOS: endometrial

cancer, cardiovascular and metabolic risks”, “After the WHI: How does it affect practice in 2008?”

2009 Western AFMR Carmel Ca, “Writing Successful Grant Proposals”

7

2009 Clinical Endocrinology and Diabetes Meeting, Snowmass CO: “Traumatic Brain Injury: when to look, when to treat”, “New insights into the diagnosis and treatment of Acromegaly”

2009 Endocrine Disorders and Female Sexual Function, International meeting on Sexual Function, Paris, France

2010 Meet the Professor, The Endocrine Society, San Diego, CA, “Androgen Excess in Postmenopausal Women”

2011 Clinical Endocrinology and Diabetes Meeting, Snowmass CO: “Acromegaly: New treatment strategies and outcomes”, “Male Hypogonadism: a new Metabolic risk Factor?”, “Hair, hair everywhere: cases of hyperandrogenism in women”

2011 Meet the Professor, The Endocrine Society, Boston, MA, “Evaluation of Postmenopausal Androgen Excess”

2011 AVIM Forum, Denver, CO, “An update on Acromegaly in humans” 2011 Cardiometabolic Health Congress, Boston, MA, “Cardiovascular implications of Hormone

Therapy in Menopause” 2011 National CARES Foundation Congenital adrenal hyperplasia Education Day, “Hormonal

therapy options in adult CAH patients” 2012 Colorado Society of Endocrinology and Diabetes Meeting, Snowmass, CO “Metabolic

effects of hypogonadism”, Update on acromegaly” 2012 University of Washington Endocrine Days, “Consideration of Hirsutism and androgen

excess in the menopause”; Revisiting Hormone Therapy in Menopause-Where are we in 2012?”

2012 International Congress of Endocrinology, Florence, IT, “Fertility options for young patients with panhypopituitarism”

2012 Clinical Endocrine Update, The Endocrine Society, Miami, Fl “Hormone Therapy in 2012” 2012 International Diabetes and Endocrinology Congress, Dubai UAI “Pituitary Tumor Cases”,

Update in Osteoporosis” 2013 British Endocrine Society, Leeds UK, Keynote symposia, “Understanding the

Pathogenesis of Gonadotrope Pituitary Tumors”. 2013 International congress on Acromegaly, Amsterdam, Netherlands, chair “Optimal medical

therapy postoperative for GH tumors” 2013 The Endocrine Society, San Francisco, CA, symposia, “Oxidatative Stress and Hypoxia-

Induced Signaling Pathways in Pituitary Tumorigenesis” 2013 Clinical Endocrine Update, The Endocrine Society, New Orleans, LA, “ Female Sexual

Dysfunction”, “Update in PMP Hormone Therapy”, Board review Female Reproduction 2013 Massachusetts General Hospital, Harvard, Endocrine Grand Rounds, Boston, MA “ Roles

of TAM (Tyro3, AXL and Mer) tyrosine kinases in GnRH neuron biology and patients with IHH”

2013 Brigham and Women’s Hospital, Harvard, Endocrine Grand Rounds, Boston, MA “Identification of a Novel Kinase that Promotes Pituitary Tumorigenesis and Survival in Response to Hypoxia”

2014 Endocrine Grand Rounds, University of Colorado, “Testosterone and Cardiovascular Risk: What do the Epidemiologic Data Tell Us?”

2014 4th Emirates Diabetes and Endocrine Congress, Dubai UAI, “Management of Menopause”, How Should we Evaluate Women with Androgen Excess?” “Polycystic Ovarian Syndrome: Cases Across the Life of Women”

2014 University of Texas Southwestern Medical School, Endocrine Grand Rounds, Dallas, TX “Genetic and Genomic Screens to Identify Novel Targets in Pituitary Tumorigenesis”

2014 Cedar Sinai, UCLA, Los Angeles, CA, Endocrine Research Series, “Role of MST4 in Hypoxia Pathways to Pituitary Tumorigenesis”

2014 Female Reproduction section, Endocrinology Board Review, Clinical Endocrine Update, the Endocrine Society, San Francisco, CA

8

2014 Diabetes Endocrinology Summit, Mumbai India “Testosterone and Cardiovascular Risk: Putting the Epidemiologic Data in Perspective”, “Postmenopausal Hormone Therapy in 2014”

2015 Colorado Society of Endocrinology and Metabolism Snowmass CO “What’s New in PCOS”, “Case series on Hypogonadism”

2015 American College of Physicians Colorado Chapter “Testosterone Risks and Benefits”, Colorado Springs CO

2015 Endocrine Grand Rounds, University of Colorado, “Azoospermia :New Molecular Insights into Etiology and Treatment”

2015 Spanish Endocrine Society Congress, Madrid Spain, “Molecular Pathogenesis of Pituitary Tumors”

2015 American Association of Clinical Endocrinogists national meeting “Testosterone Therapy in 2015” , “PCOS across the lifespan” Nashville, Tenn

2015 Kaiser health national Primary Care meeting “Testosterone Therapy in Men: Putting the Epidemiologic Data in Perspective”, San Diego, CA

2015 Boston University Visiting Professor, Endocrine Grand Rounds “ An Update on Menopausal Therapy in 2015”, Boston, MA

Trainees (postdoctoral):

1990-1995 Jadwiga K. Kepa, Ph.D. Postdoctoral fellow 1990-1995 Jan M. Bruder, M.D. Postdoctoral fellow 1992-1994 Kenneth A. Faber, M.D. Assistant Professor, Obstetrics and

Gynecology 1995-1996 Zhaoqin Fang, M.D. Visiting Scientist from China 1996-1998 Xiaoyan Xiong, Ph.D. Postdoctoral fellow, UCD 1998-1999 Carol Sable, Ph.D. Postdoctoral fellow, UCD 1998-2002 Melissa Allen, Ph.D. Postdoctoral fellow, UCD 2000-2001 Patrick J. Silva, Ph.D. Postdoctoral fellow, UCD 2000-2001 Shiping Wang, Ph.D. Visiting Scientist from China 2000-2005 John Pawlowski, Ph.D. Instructor in Medicine, UCDHSC 2001-2004 Dong Wang, PhD. Postdoctoral fellow, UCD 2003-2006 Sheila Nielson-Preiss, PhD Assistant Professor, UWyoming 2004-2006 Micol S. Rothman, MD Associate Professor, UCD 2005-2006 Lynnette Shorts Cary PhD Postdoctoral fellow, UCD 2006-2007 Megan Moriarty, MD Pediatric Endocrine fellow 2006-2011 Aimee Meditz, MD Asst Prof in Medicine, InfD (K08) 2007-2010 Angela Pierce, PhD Posdoctoral fellow, UCD 2007-2011 Aaron Knox, PhD Instructor, UCD 2008-2012 Nichole Carlson PhD Associate Professor Biostats (K08) 2010- Katja Kiseljak-Vassiliades, DO Assistant Professor, UCSOM 2011- Smita Mehta, PhD Postdoctoral fellow, UCSOM 2012-2012 Maozhen Tian, PhD Instructor fellow, UCSOM 2013-2015 Weipeng Xiong, PhD Postdoctoral fellow, UCSOM 2013-2015 Nikita Pozdeyev MD PhD, mentoring team Postdoctoral fellow, UCSOM 2015- Natalie Nokov MD, mentoring team Postdoctoral fellow, Pediatrics

Trainees (students): Current position

1991 William Krebs, University of Miami Researcher, marine biology 1992 Pravin Rao, high school student John Hopkins Medical School 1992 Kathy Ann Velasquez, University of Colorado 1993 Erik T. Price, University of Colorado Medical student, UCD 1994 Charles Tate, University of Colorado

9

1994 Jennifer Adams, University of Colorado 1995 Tien Nguyen, University of Colorado Medical student, UCD 1995 Brenda Canniff, University of Denver Industry 1996 Julie Rain, Middlebury College Medical School 1997 Michelle Sleater, Yale University 1998 Ted Leem, University of Colorado Medical student, UCD 1998 Michelle Sleater, Yale University MD-PhD student, UCD 1999 Carrie Schwartz, Endocrine Society Fellowship Resident in Ob/Gyn 2000 Scott Greenberg, University of Colorado UCDHSC Undergraduate 2001 Rachel Martinkus, Denver Univ.(honors thesis) Undergraduate at DU 2001 Lisa Hubbard, Univ. of Northern Colorado Medical student, UCD 2002 Matthew Hotchkiss UC Boulder 2002 Noelle Diltz UC Boulder 2003 Logan Thomas UC Boulder 2003 Kristen Brown Northwestern University 2004 Margaret Lotts Medical student, UCD 2004 Danielle McDermott Medical student, UCD 2003-04 James Haughian Graduate Student, PiRS, UCD 2004-05 Howard Li, MD Assistant Professor, UCD 2005 Sean Ronneikiev-Kelly Medical student, UCD 2007 Cari O’Driscoll Undergraduate student, CSU 2008 Sierrra McNamara Notre Dame University 2009 Melinda Schaller Wayne State Medical School 2009-11 Katy Michaelis Oregon Health and Science Univ 2011-14 Emily Busta Reproductive Science Grad student 2012 Eamon Quick Neuroscience Graduate student 2013 Ally Booth Reproductive Science Grad student 2015 Leyda Villagrasa Puerto Rico, Endo Society fellowship 2015 Raud Razzaghi Arizona State summer student 2015 Alanna Hernandez Metro State summer student

Administrative, Clinical and Research Expertise: Administrative: As Chief of Endocrinology at the VA I supervise 5 faculty, 3 nurse practitioners, 1 certified diabetes educator and administrative staff. We have a successful integrated program that combines in person consultative practice with ENDO TELE health for our VISN, ENDO Electronic E Consult program which has grown from 50 to 650 consults/year and ENDO ECHO SCAN programs in diabetes and endocrinology to provide subspecialty care outreach to veterans and primary providers. We have just received funding for PEERS: Program in Endocrine/Diabetes Education in Rural Settings which will test the effectiveness of 3 pilot models to improve care: Immersion Program, Transition of Care and TEAM clinics and provide funding for faculty NP, CDE and administrative staff.

At the University of Colorado, my focus is Reproductive Medicine and Pituitary disorders and have built a Pituitary Program with expansion of clinical, educational and research efforts in pituitary disorders. I supervise 2 faculty, 1 administrative staff and work closely with colleagues in neurosurgery, neuropathology and Neuro-oncology. We currently have 4-5 clinical research protocols ongoing. We have also created a multidisciplinary Adrenal Neuroendocrine Tumor program to build a clinical team with concomitant research and educational arms.

Within the UCSOM CTSA, I organized and run the KTR program which pre-reviews R type applications of K awardees or other junior investigators with an in house mock study section 3 times/yr that the applicants attend to improve their understanding of the review process and successful competition for R funding. Our outcome measures show increased funding success rates higher than national averages.

10

Clinical: Reproductive Endocrinology, pituitary and adrenal disease (2-1/2d clinics/wk, 1 mo endo attending, 2 wks Medicine attending) Expertise in endocrinology, with focus in hormonal disorders in women and men, pituitary tumors and adrenal and other endocrine neoplasms.

Research: -Our lab is interested in the ontogeny of the GnRH neuronal system, the developmental control of GnRH synthesis by peptide and steroid hormones and regulation of neuronal migration. Recent efforts focus on the epigenetic role of Class II histone deacetylases (HDACS) to modulate the developmental program of GnRH neurons. Insight into the control of the GnRH neuronal network may shed light on the normal physiology of the reproductive axis, a better understanding of the pathophysiology of the system and new treatment options for patients.

-A second translational focus is in the molecular pathogenesis of pituitary tumors. Using molecular and bioinformatics approaches we have identified novel candidates involved in pituitary tumors causing altered proliferation, migration and invasion. Analysis of human tumors coupled with use of mouse models and cell systems to explore mechanisms may give new biomarkers that can be used clinically for aggressiveness and lead to new treatments for our patients. We recently have identified a novel kinase, MST4, which mediates tumorigenesis and survival in response to hypoxia,that may prove to be a new targetable kinase in pituitary tumors. Other studies are identifying histologic and molecular markers for aggressiveness in GH tumors to predict response to medical therapies and dissect underlying mechanisms.

-Clinical research projects include: -Understanding the role of sex steroids in recovery from traumatic brain injury: I am coPI on a clinical investigation of the effects of testosterone therapy to hypogonadal men after TBI on the functional rate of recovery and neurocognitive response to acute rehabilitation. This is a placebo controlled study of physiologic testosterone therapy during an acute rehabilitation program after TBI. -We have 2 industry trials of the use of weekly compared to daily GH therapy for patients with hypopituitarism -We participate in a national database of patients with acromegaly being treated with a GH receptor antagonist -We are funded to test the effectiveness of a novel drug to treat recurrent Cushings syndrome -We are negotiating a trial of an oral somatostatin analog for treatment of acromegaly

Current research projects: 1. VA Merit Review; “Role of Mammalian Ste20 related kinase 4 (MST4) in pituitary tumors”, Role:

PI 7/1/13-3/31/17. 2. Colorado Brain Trust; “Neuroendocrine dysfunction in traumatic brain injury, (Role CoPI with

David Ripley, Craig Hospital) 4/10-9/15. 3. Prolor “Weekly GH for GH deficient adults” phase IV study, Role PI, “To assess the effectiveness

and safety of a once weekly formulation of GH for GH deficient patients” 2014-2016 4. Novonordisk REAL trial of weekly growth hormone in patients with GH deficiency 2015- (role co-

Investigator. 5. Novartis LLCI trial of new therapeutic for Cushings syndrome 2015- (role Co Investigator)

6. K12 Calebresi Award to Katja Kiseljak Vasilliades (role Mentor) 7. PEERS Program in Endocrine /Diabetes Education in Rural Settings: Rural Health Veterans

Affairs. This is a program to educate primary care providers in diabetes and endocrine disorders using new models of education and management, employing Immersion program, TELE health, E consult , Transition of care, TEAM clinics( funding for VA faculty, NP, CDE and support staff).

8. Cancer League of Colorado, “Targeting MST4 in Pediatric Brain Cancer” 2015-16 to identify the role of a novel kinase in pediatric brain tumors.

Pending:

11

1. R21 “Targeting the MST4 kinase in Tumorigenesis” Role Co-PI with a goal of developing novel MST4 kinase inhibitors using computer modeling and functional studies.

2. RO1, “ Role of Class II Histone Deacetylases in GnRH Neuron Development and Function” Role PI, to be submitted 10/15.

Recently completed research projects:

1. Pfizer “Predicting response to medical therapy in Acromegaly” (Role PI) investigator initiated project to examine clinical and biomarkers of response or nonresponse to somatostatin analog and GH receptor antagonist therapy 9/12-8/14

2. Novartis “Somatostatin receptor subtype expression in Growth hormone tumors in Acromegaly”. To determine the expression profiles mRNA and protein for all somatostatin receptor subtyping in various types of GH tumors to predict response to therapy. 5/13-9/14

Publications: 1. Wierman ME, Beardsworth DE, Mansfield MJ, Badger TM, Crawford JD, Crigler JF, Bode HH,

Loughlin JS, Kushner DC, Scully RE, Hoffman WH, Crowley WF: Puberty without gonadotropins: A unique mechanism of sexual development. New England Journal of Medicine 1985 312:65-72.

2. Wierman ME, Beardsworth DE, Crawford JD, Crigler JF, Mansfield MJ, Bode HH, Boepple PA,

Kushner DC, Crowley WF: Adrenarche and skeletal maturation during luteinizing hormone release hormone analogue suppression of gonadarche. Journal of Clinical Investigation 1986 77:121-126.

3. Santoro N, Wierman ME, Filicori M, Waldstreicher J, Crowley WF: Intravenous administration of

pulsatile gonadotropin-releasing hormone (GnRH) in hypothalamic amenorrhea: Effects of dosage. Journal of Clinical Endocrinology & Metabolism 1986 62:109-116.

4. Gharib SD, Wierman ME, Badger TM, Chin WW: Sex-steroid hormone regulation of

follicle-stimulating hormone (FSH) subunit messenger ribonucleic acid (mRNA) levels in the rat. Journal of Clinical Investigation 1987 80:294-299.

5. Childs GV, Lloyd JM, Unabia G, Gharib SD, Wierman ME, Chin WW: Detection of LHß mRNA

levels in individual gonadotropes after castration: Use of a new in situ hybridization method with a photobiotinylated cRNA probe. Molecular Endocrinology 1987 1:926-932.

6. Wierman ME, Gharib SD, LaRovere JM, Badger TM, Chin WW: Selective failure of androgens to

regulate follicle-stimulating hormone ß messenger ribonucleic acid levels in the male rat. Molecular Endocrinology 1988 2:492-498.

7. Gharib SD, Roy A, Wierman ME, Chin WW: The beta subunit of rat follicle stimulating hormone

gene: analysis of structure and nucleotide sequence. DNA 1989 8:339-349.

8. Wierman ME, Rivier JE, Wang C: Gonadotropin-releasing hormone-dependent regulation of gonadotropin subunit messenger ribonucleic acid levels in the rat. Endocrinology 1989 124:272- 278.

9. Samuels MH, Wierman ME, Wang C, Ridgway EC: The effect of altered thyroid status on

pituitary hormone messenger ribonucleic acid concentrations in the rat. Endocrinology 1989 124:2277-2282.

12

10. Childs GV, Unabia G, Wierman ME, Gharib SD, Chin WW: Castration induces time-dependent changes in the FSHß-mRNA-containing gonadotrope cell population. Endocrinology 1990 126:2205-2213.

11. Wierman ME, Gharib SD, Wang C, LaRovere JM, Badger TM, Chin WW: Divergent regulation of

gonadotropin subunit mRNA levels by androgens in the female rat. Biology of Reproduction 1990 43:191-195.

12. Martin K, Santoro N, Hall J, Filicori M, Wierman ME, Crowley WF Jr: Management of ovulatory

disorders with pulsatile gonadotropin-releasing hormone. Journal of Clinical Endocrinology & Metabolism 1990 71:1081A-1081G.

13. Wierman ME, Wang C: Androgen selectively stimulates follicle-stimulating hormone-ß mRNA

levels after gonadotropin-releasing hormone antagonist administration. Biology of Reproduction 1990 42:563-571.

14. Kepa JK, Wang C, Neeley CI, Raynolds MV, Gordon DF, Wood WM, Wierman ME: Structure of

the rat gonadotropin releasing hormone (rGnRH) gene promoter and functional analysis in hypothalamic cells. Nucleic Acids Research 1992 20:1393-1399.

15. Wierman ME, Kepa JK, Sun W, Gordon DF, Wood WM: Estrogen negatively regulates rat

gonadotropin releasing hormone (rGnRH) promoter activity in transfected placental cells. Molecular and Cellular Endocrinology 1992 86:1-10.

16. Boepple PA, Frisch LS, Wierman ME, Hoffman WH, Crowley WF Jr: The natural history of

autonomous gonadal function, adrenarche and central puberty in gonadotropin-independent precocious puberty. Journal of Clinical Endocrinology & Metabolism 1992 75:1550-1555.

17. Bruder JM, Krebs WD, Nett TM, Wierman ME: Phorbol ester activation of the protein kinase C

pathway inhibits gonadotropin-releasing hormone gene expression. Endocrinology 1992 131:2552-2558.

18. Cryns VL, Thor A, Xu H-J, Hu S-X, Wierman ME, Vickery AL Jr, Benedict WF, Arnold A: Loss of

the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. New England Journal of Medicine 1994 330:757-761.

19. Bruder JM, Wierman ME: Evidence for transcriptional inhibition of GnRH gene expression by

phorbol ester at a proximal promoter region. Molecular and Cellular Endocrinology 1994 99:177- 182.

20. Kepa JK, Neeley CI, Jacobsen BM, Bruder JM, McDonnell DP, Leslie KK, Wierman ME:

Estrogen receptor mediated regulation of rat gonadotropin releasing hormone (GnRH) promoter activity in hypothalamic cells. Endocrine 1994 2:947-956.

21. Bruder JM, Samuels MH, Bremner WJ, Ridgway EC, Wierman ME: Hypothyroidism-induced

macroorchidism: Use of a gonadotropin-releasing hormone agonist to understand its mechanism and augment adult stature. Journal of Clinical Endocrinology and Metabolism 1995 80:11-16.

22. Wierman ME, Bruder JM, Kepa JK: Regulation of gonadotropin-releasing hormone (GnRH)

gene expression in hypothalamic neuronal cells. Cellular and Molecular Neurobiology 1995 15:79-88.

13

23. Bruder JM, Spaulding AJ, Wierman ME: Phorbol ester inhibition of rat gonadotropin-releasing hormone promoter activity: Role of Fos and Jun in the repression of transcription. Molecular Endocrinology 1996 10:35-44.

24. Wierman ME, Fang Z, Kepa JK: GnRH gene expression in neuronal cell lines. Trends in

Endocrinology and Metabolism 1996 7:60-65. 25. Kepa JK, Jacobsen BM, Boen EA, Prendergast P, Edwards DP, Takimoto G, Wierman ME:

Direct binding of progesterone receptor to nonconsensus DNA sequences represses rat GnRH. Molecular and Cellular Endocrinology 1996 117:27-39.

26. Kepa JK, Spaulding AJ, Jacobsen BM, Fang Z, Xiong X, Radovick S, Wierman ME: Structure of

the distal human gonadotropin releasing hormone (hGnRH) gene promoter and functional analysis in GT1-7 neuronal cells. Nucleic Acids Research 1996 24:3614-3620.

27. Wierman ME, Xiong X, Kepa JK, Spaulding AJ, Jacobsen BM, Fang Z, Nilaver G, Ojeda SR:

Repression of gonadotropin-releasing hormone promoter activity by the POU homeodomain transcription factor SCIP/Oct-6/Tst-1: A regulatory mechanism of phenotype expression? Molecular & Cellular Biology 1997 17:1652-1665.

28. Fang Z, Xiong X, James A, Gordon DF, Wierman ME: Identification of novel factors that regulate

GnRH gene expression and neuronal migration. Endocrinology 1998 139:3654-3657. 29. Wierman ME: Decision making in medicine: Erectile dysfunction: A multifaceted disorder.

Hospital Practice 1998 33:65-90. 30. Allen M, Zeng C, Schneider K, Xiong X, Meintzer MK, Bellosta P, Basilico C, Varnum B,

Heidenreich KA, Wierman ME: Growth arrest specific gene 6 (Gas6)/adhesion related kinase (Ark) signaling promotes gonadotropin releasing hormone (GnRH) neuronal survival via Akt and ERK. Molecular Endocrinology 1999 13:191-201.

31. Allen MP, Xu M, Zeng C, Tobet SA, Wierman ME: Myocyte endhancer factors-2B and 2C are

required for adhesion related kinase (Ark) repression of neuronal Gonadotropin releasing hormone (GnRH) gene expression. Journal of Biological Chemistry 2000 275: 39662-39670.

32 Li M, Allen MP, Meintzer MK, Linseman DA, Wang X, Laessig T, Wierman ME, Heidenreich KA:

Myocyte enhancer factor 2A and D undergo phosphorylation and caspase-mediated degradation during apoptosis of rat cerebellar granule neurons. J Neuroscience 2001 21: 6544-6452 .

33. Allen MP, Linseman DA, Udo H, Xu M, Schaack JB, Varnum B, Kandel ER, Heidenreich KA,

Wierman ME: Novel mechanism for gonadotropin-releasing hormone neuronal migration involving Gas6/Ark signaling to p38 mitogen-activated protein kinase. Molecular and Cellular Biology 2002 22:599-613.

34. Pawlowski JE, Ertel JR, Allen MP, Xu M, Butler C, Wilson EM, Wierman ME: Liganded androgen

receptor interaction with β-Catenin, J Biological Chemistry 2002 277:20702-20710. 35. Vazquez-Martinez R, Leclerc GM, Wierman ME, Boockfor FR: Episodic activation of the rat

GnRH promoter: Role of the homeprotein Oct 1, Molecular Endocrinology 2002 16:2093-2100. 36. Allen MP, Xu M, Linseman DA, Pawlowski JE, Bokoch GM, Heidenreich KA, Wierman ME:

Adhesion related kinase (ARK) repression of gonadotropin releasing hormone (GnRH) gene

14

expression requires RAC activation of the extracellular signal-regulated kinase (ERK) pathway, J Biological Chemistry 2002 277:38133-39140.

37. Petroff BK, Croutch CR, Hunter DM, Wierman ME, Gao X: 12,3,7,8-Tetrachlorodibenzo-p-dioxin

(TCDD) stimulates gonadotropin secretion in the immature female Sprague-Dawley rat through a pentobarbiatal-and estradiol-sensitive mechanism but does not alter gonadotropin-releasing hormone (GnRH) secretion by immortalized GnRH neurons in vitro. Biol Reprod 2003 68:2100- 2106.

38. Hirshman E, Wells E, Wierman ME, Anderson B, Butler A, Senholzi M, Fisher J: The effect of

Dehydroepiandrosterone (DHEA) on recognition memory decision processes and discrimination in post-menopausal women. Psychon Bull Rev 2003 10: 125-134.

39. Shattuck TM, Kim TS, Costa J, Yandell DW, Imanishi Y, Palanisamy N, Gaz RD, Shoback D,

Clark OH, Monchik JM, Wierman ME, Hollenberg A, Tojo K, Chaganti RS, Arnold A: Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in parathyroid carcinoma. Clin Endocrinol 2003 59: 180-189.

40. Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K,

Robbins CM, Carpten JD, Farnebo LO, Larsson C, Arnold A: Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 2003 349: 1722-1729.

41. Wierman ME, Pawlowski J, Allen MP, Linseman DA, Xu M, Nielsen-Preiss S: Molecular

mechanism of Gonadotropin releasing hormone neuronal migration. Trends Endocrinol Metab 2004 15:96-102.

42. Costa J, Shattuck TM, Imanishi Y, Palanisamy N, Gaz RD, Shoback D, Clark OH, Monchik JM,

Wierman ME, Hollenberg A, Tojo K, Chaganti RSK, Arnold A: Mutational analyses of connexin 26, connexin 30 and connexin 46 as candidate tumor suppressor genes in parathyroid carcinoma. J Endocrine Genetics 2004.

43. Hirshman E, Merrittt P, Wang CCL, Wierman ME, Budescu DV, Kohrt W, Templin JL, Bhasin S:

Evidence that androgenic and estrogenic metabolites contribute to the effects of dehydroepiandrosterone on cognition in postmenopausal women. Hormones and Behavior 2004 45: 144-155.

44. Harrison, GS, Wierman ME, Nett TM, Glode LM: GnRH and its receptor in normal and malignant

cells. Endocrine Related Cancer 2004 11(4):725-48. . 45. Wierman ME, Basson R, Davis SR, Khosla S, Miller K, Rosner W, Santoro N: Clinical practice

guideline: The therapeutic use of androgens in women: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2006 91:3697-3716.

46. Cary LS, Xu M, Ertel J, Kleinschmidt-DeMasters BK, Lillehei K, Matsuoka I, Nielsen-Preiss S,

Wierman ME: Bone Morphogenetic protein and retinoic acid inducible neural specific protein-3 (BRINP3) is expressed in gonadotrope cell pituitary adenomas and induces proliferation, migration and invasion gonadotropinomas. Endocrinology 2007 Mar;148(3):967-75.

47. Allen MP, Nielson-Preiss SM, Xu M, Linseman DA, Pawlowski JE, Bouchard R, Heidenreich KA,

Wierman ME: Adhesion Related Kinase Induction of Migration Requires PI3-kinase and Ras Stimulation of Rac Activity in immortalized GnRH neuronal cells. Endocrinology. 2007;148:2806- 14.

15

48. Wierman ME: Sex steroid effects at target tissues: mechanisms of action. Adv Physiol Educ. 2007;31:26-33.

49. Rothman MS, Arciniegas DB, Filley CM, Wierman ME: The neuroendocrine effects of traumatic

brain injury. J Neuropyschiatry and Clinical Neurosciences. 2007;19:363-72.. 50. Schwarting G, Wierman ME, Tobet S: GnRH Neuronal Migration. 2007;25:305-12.

51. Wierman ME, Kohrt WM: Vascular and metabolic effects of sex steroids: new insights into clinical trials. Reprod Med 2007 25:305-12.

52. Rothman MS, Wierman ME: The role of GnRH in normal and pathologic endocrine processes.

Current Opinion in Endocrinology and Diabetes. 2007; 14: 306-10. 53. Wierman M, Basson R, Davis S, Khosla S, Miller K, Rosner W, Santoro N: Are the endocrine

society’s clinical practice guidelines on androgen therapy in women misguided? A commentary- response. J Sex Med 2007 4:1782-83.

54. Rothman MS, Wierman ME: Testosterone and cardiovascular disease in men. Aging Health

2007. 55. Rothman MS, Wierman ME: Female hypogonadism: Evaluation of the hypothalamic-pituitary-

ovarian axis. Pituitary 2008 11:163-9. 56. Pierce AM, Bliesner B, Xu M, Nielsen-Preiss S, Lemke G, Tobet S, Wierman ME: Axl and tyro3

modulate female reproduction by influencing gonadotropin releasing hormone (GnRH) neuron survival and migration. Molecular Endocrinology 2008 22:2481-95.

57. Giustina A, Barkan A, Chanson P, Grossman A, Hoffman A, Ghigo E, Casanueva F, Colao A,

Lamberts S, Sheppard M, Melmed S: Pituitary Society; European Neuroendocrine Association: Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest 2008 31: 820-38.

58. Xu M, Shorts-Cary L, DeMasters BK, Lillehei K, Wierman ME: Epidermal growth factor substrate

(Eps8) is upregulated in human pituitary tumors: role in proliferation and survival. Endocrinology 2009 150:2064-71.

59. Meditz AL, Wierman ME, Connick E. The Impact of Hormonal Contraception on the HIV-1

Epidemic, European Infectious Diseases 2008 2: 43-47. 60. Rothman MS, Wierman ME: Low testosterone levels and the risk of metabolic syndrome in men

2009.Aging Health. 61. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P,

Laws E, Schlechte J, Vance ML, Ho K, Guistina A: Acromegaly consensus group. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009 94: 1509-17.

62. Carlson NE, Brenner LA, Wierman ME, Harrison-Felix C, Morey C, Gallagher S, Ripley D:

Hypogonadism on admission to acute rehabilitation is correlated with lower functional status at admission and discharge. Brain Injury 2009 23:336-44.

63. Salvatori R, Nachtigall LB, Cook DM, Bonert V, Molitch ME, Blethen S, Chang S: SALSA

STUDY group. Effectiveness of self or partner administration of ann extended release aqueous

16

gel formulation of lanreotide in lanreotide naive patients with acromegaly. Pituitary 2010 13: 115- 122.

64. Basson R, Wierman ME, van Lankveld J, Brotto L. Summary of the recommendations on the

sexual dysfunctions in women. J Sex Med 2010 7:314-26. 65. Wierman ME, Nappi RE, Avis N, Davis SR, Sabrie F, Rosner W, Shifren JL. Endocrine aspects

of women’s sexual function. J Sex Med 2010 7: 561-85. 66. Lillehei KO, Widdel L, Arias Astete CA, Wierman ME, Kleinschmidt-DeMasters B, Kerr JM.

Transpenoidal resection of 100 rathke’s cleft cysts: limited value of alcohol cauterization in reducing recurrence rates. JNeurosurgery 2011 114:310-7.

67. Wierman ME, Kiseljak-Vassilliades K, Tobet S. Gonadotropin Releasing Hormone (GnRH)

Neuronal Migration : Initiation, Maintenance and Cessation as Critical Steps to Ensure Normal Reproductive Function. Frontiers in Neuroscience 2011 32:43-52.

68. Rothman M, Carlson N, Xu M, Goh V, Lee W, Swerdloff R, Ridgway EC, Wang C, Wierman ME.

Reexamination of Testosterone, Dihydrotestosterone, Estradiol and Estrone Levels Across the Menstrual Cycle and in Post Menopausal Women Measured by Liquid Chromatography Tandem Mass Spectrometry Steroids 2011 76:177-82.

69. Rothman MS and Wierman ME. How should postmenopausal androgen excess be evaluated?

Clinical Endocrinology 2011 75:160-164. 70. Kerr JM, Wierman ME. Pituituary apoplexy. BMJ 2011 342:1270.

71. Madsen H, Borges TM, Knox AJ, Michaelis KA, Xu M, Lillehei KO, Wierman ME and Kleinschmidt DeMasters B. Giant Pituitary Adenomas: pathologic-radiographic correlations and lack of role for p53 and MIB-1 labeling. American Journal of Surgical Pathology, 2011 35:1204- 1213.

72. Michaelis KA, Knox AJ, Xu M, Kiseljak-Vassiliades K, Edwards ME, Geraci M , Kleinschmidt-

DeMasters B, Lillehei KO, Wierman ME. Identification of Growth Arrest and DNA-Damage- Inducible Gene β (GADD45β) as a Novel Tumor Suppressor in Pituitary Gonadotrope Tumors Endocrinology 2011 152:3603-13.

73. Wierman ME, Xu M, Pierce A, Bliesner B, Bliss SP, Roberson MS. Extracellular Signal-regulated

Kinase (ERK) 1 and ERK2 are not Required for GnRH Neuron Development and Normal Female Reproductive Axis Function in Mice. Neuroendocrinology, 2012 95:289-96.

74. Knox AJ, Xu M, Michaelis KA, Kleinsmidt-DeMasters B, Lillehei KO, Wierman ME. Reprimo

(RPRM) is Downregulated in Human Gonadotrope Pituitary Tumors and protein levels upregulated with cellular stress. Endocrinology 2012 153:2963-73.

75. Meditz AL, Moreau KL, MaWhinney S, Gozansky WS, Melander K, Kohrt, WM, Wierman, ME,

and Connick E. CCR5 Expression is Elevated on Endocervical CD4+ T-Cells in Healthy Postmenopausal Women, JAIDS 2012 59:221-228.

76. Weickhardt AJ, Rothman M,Salian-Mehta S, Kiseljak-Vassiliades K, Oton AB, Doebele RC,

Wierman ME, Cambidge DR. Rapid Onset Hypogonadism secondary to Crizotinib Use in Men with Metastatic Non-small cell Lung Cancer. Cancer 2012 118: 5302-9.

17

77. Kiseljak-Vassiliades K, Shafi S, Kerr JM, Phang TL, Kleinschmidt-DeMaster BK, Wierman ME. Clinical Implications of Growth Hormone-Secreting Tumor Subtypes. Endocrine. 2012; 42(1):18- 28. PMID: 22434413.

78. Weickhardt AJ, Doebele RC, Purcell WT, Bunn PA, Oton AB, Rothman MS, Wierman ME, Mok

T, Popat S, Bauman J, Nieva J, Novello S, Ou SH, Camidge DR. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer. 2013 119(13):2383-90.

79. Salian-Mehta S, Xu M and Wierman ME. AXL and MET Crosstalk to Promote Gonadotropin

Releasing Hormone (GnRH) Neuronal Cell Migration and Survival, Mol Cell Endocrinol. 2013 374(1-2):92-100.

80. Rosner W, Hankinson SE, Sluss P, Vesper HW, Wierman ME. Challenges to the Measurement

of Estradiol An Endocrine Society Position Statement, J Clin Endocrinol Metab 2013 98(4):1376-87.

81. Vigen R, O’Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, Barqawi A,Woning,

G, Wierman ME, Plomondon ME, Rumsfeld JS, Ho PM. Association of Testosterone Therapy with Mortality, Myocardial Infarction and Stroke in Men with Low Testosterone Levels JAMA 2013 310:1829-1836.

. 82. Mehta SM, Knox AJ, Xu M, Plummer L,Slavov D, Taylor M, Bevers S, Hodges RS, Crowley WF

Jr,. Wierman ME. AXL Sequence Variants Implicate the TAM (Tyro3, Axl, Mer) Pathway in the Isolated Hypogonadotropic Hypogonadism JCEM 2014 Apr;99(4):1452-60.

83. Ho PM, Barón AE, Wierman ME Deaths and cardiovascular events in men receiving

testosterone--reply. JAMA. 2014 Mar 5;311(9):964-5. 84. Salian-Mehta,S Xu M, Pierce A, Bliesner B, Tobet S, Wierman ME. Reproductive Phenotype of

Gas6 null mice implicate ligand independent actions of TAM (Tyro3, Axl and Mer) receptors in GnRH neuron development. Mol Cell Endocrinol 2014 Aug 5;393(1-2):164-70.

85. Kiseljak-Vassiliades K, Carlson NE, Borges MT, Kleinschmidt-DeMasters BK, Lillehei KO, Kerr

JM and Wierman ME. Growth Hormone Tumor Histological Subtypes Predict Response to Surgical and Medical Therapy. Endocrine. 2014 E pub, Aug 17.

86. Wierman ME, Arlt W, Basson R, Davis SR, Miller KK, Murad MH, Rosner W, and Santoro N.

Androgens in Women a reappraisal: the Endocrine Society Clinical Guideline, J Clin Endocrinol Metab 2014 Oct;99(10):3489-510

87. Cefalu WT, Nair KS, Seaquist ER, Zierath J, Boulton AJ, LeRoith D, Harrell RM, Grunberger G,

Wartofsky L, Gore AC, Wierman ME, Hammes SR, Lange CA, Santen RJ. Statement of principle. Endocr Rev. 2014 Dec;35(6):850.

88. Sato J, Kinugasa M, Satomi-Kobayashi S, Hatakeyama K, Knox AJ, Asada Y, Wierman ME,

Hirata K, Rikitake Y.Family with sequence similarity 5, member C (FAM5C) increases leukocyte adhesion molecules in vascular endothelial cells: implication in vascular inflammation. PLoS One. 2014 Sep 24;9(9):e107236.

89. Wierman ME, Auchus RJ, Haisenleder DJ, Hall JE, Handelsman D, Hankinson S, Rosner W,

Singh RJ, Sluss PM, Stanczyk FZ The new instructions to authors for the reporting of steroid

18

hormone measurements. Endocr Rev. 2014 Dec;35(6):849. (also published in JCEM, Endocrinology and Hormones in Cancer).

90. Ripley D, Wierman M, Gerber D, Weintraub A, Newman J. Comment on the decision to provide

testosterone supplementation to patients with traumatic brain injury. PMR. 2014 Aug;6(8):761. 91. Shea K, Melanson E, Gavin K, Gibbons E, Stavros A, Wolfe P, Kittelson J, Vondracek S,

Gozansky W, Schwartz R, Wierman M, and Kohrt W Body composition and bone mineral density after ovarian hormone suppression with and without estradiol add-back in premenopausal women. Menopause 2015 March 16 E pub.

92. Xiong W, Knox AJ, Xu M, Kiseljak-Vassiliades K, Colgan SP, Brodsky K, Kleinschmidt-

Demasters B, Lillehei K and Wierman ME. Mammalian Ste20-like Kinase 4 Promotes Pituitary Cell Proliferation and Survival under Hypoxia. Molecular Endocrinology, 2015 29:460-72.

93. Wierman ME. Risks of Different Testosterone Preparations: Too Much, Too Little, Just Right.

Invited commentary on, Layton et al Comparative safety of testosterone dosage forms. JAMA Intern Med 2015, 175:1197-8.

94. Salian-Mehta S, Xu M, McKinsey TM, Tobet S and Wierman ME. Novel Interaction of Class IIb

Histone Deacetylase (HDAC) 6 with Class IIa HDAC9 Controls GnRH Neuronal Cell Survival and Migration. In press, J Biol Chem 2015 290:14045-56. .

95. Melanson EL, Gavin KM, Shea KL, Wolfe P, Wierman ME, Schwartz RS and Kohrt WM.

Regulation of energy expenditure by estradiol in premenopausal women. Journal of Applied Physiology 2015 in press.

96. Wierman ME, Chin WW, Clemmons DR, Gagel RF, Larsen JL. Changing of the Guard. Endocr

Rev 2015 36: 345-6. 97. Kiseljak-Vassiliades K, Kleinschmidt-Demasters B, Kerr J, Lillehei K, and Wierman ME.

Differential expression of Five Somatostatin Receptor Subtypes in Growth Hormone Pituitary Tumors. Mol Cellular Endocrinol 2015, in press.

98. Xiong W, Matheson CJ, Xu M, Backos DS, Mills TS, Salian-Mehta S, Kiseljak-Vassiliades K,

Reigan P, and Wierman ME. Structure-based Screen Identification of a Mammalian Ste20-like Kinase 4 (MST4) Inhibitor with Therapeutic Potential for Pituitary Tumors, Molecular Cancer Therapeutics 2015 in revision.

Reviews: 1. Wierman ME, Crowley WF: Neuroendocrine control of the onset of puberty. IN: Human Growth:

A Comprehensive Treatise, 2nd Edition (JM Tanner, Editor), Plenum Press, 1985; 225-238. 2. Boepple PA, Mansfield MJ, Wierman ME, Rudlin CR, Bode HH, Crigler JR, Crawford JD,

Crowley WF: Use of a potent, long-acting agonist of gonadotropin-releasing hormone (GnRH) in the treatment of precocious puberty. Endocrine Reviews 1986; 7:24-33.

3. Chin WW, Gharib SD, Wierman ME: Hormonal regulation of pituitary gonadotropin gene

expression. International Symposium on contraception research for today and the ninety's, (Talwar, editor), M/S Springer Verlag, NY 1986.

19

4. Santoro N, Wierman ME, Filicori M, Waldstreicher J, Crowley WF: The physiology of GnRH in the female: Effects of the dose of GnRH upon the pituitary and gonadal responses during induction of ovulation. IN: Episodic Hormone Secretion, (TOF Wagner and M Filicori, Editors), TM Verlag, 1987; 207-218.

5. Santoro N, Filicori M, Wierman ME, Hall J, Crowley WF: Hypogonadotropic hypogonadism in

females. IN: The Episodic Secretion of Hormones, (WF Crowley and JG Hofler, Editors), John Wiley & Sons, New York, 1987; 247-256.

6. Childs GV, Lloyd JM, Unabia G, Wierman ME, Gharib SD, Chin WW: Differential regulation of

LHß and FSHß subunit gene expression: In situ hybridization studies of individual gonadotropes. IN: Neural Control of Reproductive Function, (JM Lakoski, JR Perez-Polo, EK Rassin, Editors), Alan R. Liss, Inc., 1988.

7. Wierman ME, Gharib SD, Chin WW: The structure and regulation of the gonadotropin subunit

genes. IN: Clinical Endocrinology, (MC Sheppard, Editor), WB Saunders, London 1988; 869- 889.

8. Gharib SD, Wierman ME, Shupnik MA, Chin WW: Molecular biology of the pituitary

gonadotropins. Endocrine Reviews 1990; 11:177-199. 9. Schlaff WD, Wierman ME: Endocrinology of male fertility and infertility. Current Opinion in

Obstetrics and Gynecology 1990; 2:412-417. 10. Wierman ME, Sun W, Wang C, Gordon DF, Wood WM: Control of rat gonadotropin releasing

hormone promoter activity in placental cells. IN: Modes of Action of GnRH and GnRH Analogs, (WF Crowley and PM Conn, Editors) 1992; 106-115.

11. Bruder JM, Wierman ME: Hyperthyroidism. IN: Decision Making in Reproductive

Endocrinology, (WD Schlaff and JA Rock, Editors) 1993; 34:213-217. 12. Wierman ME, Bruder JM, Kepa JK, Jacobsen BM: Regulation of gonadotropin releasing

hormone (GnRH) gene expression by steroid and peptide hormones. IN: Puberty: Basic and Clinical Aspects, (C Bergadà and JA Moguilevsky, Editors), Ares-Serono Symposia Publications, Rome, Italy, 1995; 10:63-73.

13. Wierman ME, Bruder JM, Jacobsen BM, Neeley CI, Kepa JK: Transcriptional regulation of the

GnRH gene. IN: The Neurobiology of Puberty (TM Plant and PA Lee, Editors), Journal of Endocrinology Limited, Bourne Press, Great Britain, pp. 15-24, 1995.

14. Wierman ME: Gonadotropin releasing hormone. IN: Reproductive Endocrinology, Surgery, and

Technology, (EY Adashi, JA Rock, and Z Rosenwaks, Editors), Lippincott-Raven Publishers, Philadelphia, PA, pp 665-681, 1996.

15. Wierman ME: Advances in the diagnosis and management of impotence. IN: Advances in

Internal Medicine, (RW Schrier, Editor, JD Baster, VJ Dzau, AS Fauci, Associate Editors), Mosby-Year Book Inc., St. Louis, MO, 1998; 44:1-17.

16. Wierman ME: Amenorrhea. IN: Endocrine Secrets, (MT McDermott, Editor), Hanley & Belfus,

Inc., Philadelphia, PA, 1998; 267-271.

20

17. Wierman ME, Allen MP, Zeng C, Xu M, Dowell C: Developmental control of GnRH: Role of POU homeodomain proteins. IN: Control of the onset of Puberty, (JP Bourginoun and TP Plant, editors), Elsevier Press, Amsterdam, The Netherlands, 2000.

18. Wierman ME: Hypogonadism and erectile dysfunction. IN: The Handbook of Diagnostic

Endocrinology, (JE Hall and L Nieman, editors), Humana Press, Totowa, NJ, 2000. 19. Wierman ME: Amenorrhea. IN: Endocrine Secrets, 3rd edition, (M McDermott, editor), Hanley

and Belfus, Inc, Philadelphia, PA, 2001. 20. Wierman ME: Endocrine disorders and obesity. IN: Obesity: Clinical Evaluation and Treatment

(RH Eckel, editor), Lippincott, Williams and Wilkins, Philadelphia, PA, 2001. 21. Meditz AL, Wierman ME, Connick E: The impact of hormonal contraception on the HIV-1

epidemic. European Infectious Disease, Touch briefings 2-6, 2008. 22. Rothman M, Wierman ME: Amenorrhea. IN: Endocrine Secrets, 4th edition (m McDermott,

editor), Hanley and Belfus, Inc, Philadelphia, PA, 2009. Books: 1. Wierman ME, Editor Diseases of the Pituitary: Diagnosis and Treatment, Humana Press, 1997.

Abstracts: 1. Wierman ME, Beardsworth DE, Crawford JD, Crigler JF, Bode HH, Kushner DC, Crowley WF:

Adrenarche and growth during LHRH agonist administration. Pediatric Research 1984; 502:179A.

2. Beardsworth DE, Wierman ME, Mansfield MJ, Crawford JD, Crigler JF, Bode HH, Kushner DC,

Crowley WF: Use of an LHRH agonist in the treatment of males with central precocious puberty. Pediatric Research 1984; 18:#409;169A.

3. Wierman ME, Beardsworth DE, Crawford JD, Crigler JF, Bode HH, Scully RE, Hoffman WH,

Crowley WF: Gonadarche without gonadotropins: A new mechanism of sexual maturation. Clinical Res 1984; 32(2):276A.

4. Wierman ME, Beardsworth DE, Mansfield MJ, Kushner DC, Crawford JD, Crigler JF, Bode HH,

Crowley WF: Use of an LHRH analogue in the treatment of central precocious puberty. 7th International Congress of Endocrinology 1984; 1611.

5. Santoro N, Wierman ME, Filicori M, Crowley WF: The spectrum of abnormal patterns of

gonadotropin-releasing hormone secretion in hypothalamic amenorrhea. Eastern Section, AFCR Clin Research 1984.

6. Santoro N, Wierman ME, Filicori M, Crowley WF: Intravenous administration of pulsatile

gonadotropin-releasing hormone in hypothalamic amenorrhea: Effects of dosage. Eastern Section, AFCR Clin Research 1984; 32:690A.

7. Gharib SD, Wierman ME, Badger TM, Bernstine E, Chin WW: Regulation of mRNAs encoding

the subunits of rat follicle-stimulating hormone (FSH) by gonadal steroids. The 68th Annual Meeting of the Endocrine Society 1986; 903:256.

21

8. Gharib SD, Wierman ME, Badger TM, Bernstine E, Chin WW: Hormonal regulation of follicle-stimulating hormone (FSH) subunit gene expression in the rat. Clinical Res 1986; 34:644A.

9. Boepple PA, Wierman ME, Mansfield MJ, Crawford JD, Crigler JF, Bode HH, Crowley WF:

Natural history of gonadotropin-independent precocity (GIP): Autonomous gonadal function persists following the development of central puberty. The 67th Annual Meeting of the Endocrine Society 1987; 63.

10. Childs GV, Lloyd J, Gharib SD, Wierman ME, Chin WW: Differential regulation of gonadotropin

beta subunit gene expression in individual gonadotropes. Cell Biology Meetings 1987. 11. Wierman ME, LaRovere JM, Gharib SD, Badger TM, Chin WW: Follicle-stimulating hormone

(FSH) ß mRNA levels are regulated by estrogen but not androgens in both male and female rats. Clinical Res 1988; 36:556A.

12. Wierman ME, Wang C: Gonadotropin subunit mRNA levels are differentially regulated by GnRH.

The 68th Annual Meeting of the Endocrine Society 1988; 53. 13. Samuels MH, Wierman ME, Wang C, Ridgway EC: The effect of thyroid status on pituitary

hormone mRNA levels in the rat. The 68th Annual Meeting of the Endocrine Society 1988; 1140. 14. Childs GV, Lloyd J, Unabia G, Gharib SD, Wierman ME: Studies of monohormonal FSH

gonadotropes with in situ hybridization and photobiotinylated cRNA probes for the FSHß-subunit followed by immunocytochemistry. The 68th Annual Meeting of the Endocrine Society 1988; 59.

15. Samuels MH, Wierman ME, Wang C, Ridgway EC: Altered thyroid status and rat pituitary

hormone mRNA levels: dose response and time course. Clinical Res 1989; 37:109A and 535A. 16. Wierman ME, Wang C: Divergent effects of androgen on gonadotropin subunit mRNA levels

following GnRH antagonist (GnRHA) administration in the rat. The 69th Annual Meeting of the Endocrine Society 1989; 228.

17. Gharib SD, Wierman ME, Roy A: Isolation and characterization of the gene encoding follicle-

stimulating hormone beta (FSHß) subunit in the rat. The 69th Annual Meeting of the Endocrine Society 1989; 243.

18. Wang C, Sun W, Wilson K, Wierman ME: Differential effects of a GnRH antagonist on

gonadotropin secretion and synthesis in the male rat. The 70th Annual Meeting of the Endocrine Society 1990; 454.

19. Wierman ME, Wang C, Sun W, Raynolds MV, Gordon DF, Wood WM: Negative regulation of

the rat gonadotropin releasing hormone (GnRH) gene by estrogen. The 70th Annual Meeting of the Endocrine Society 1990; 1054.

20. Wierman ME, Sun W, Wang C, Gordon DF, Wood WM: Regulation of rat gonadotropin releasing

hormone (GnRH) promoter activity in placental cells. Serono Symposium on Modes of Action of GnRH and GnRH Analogs 1991.

21. Kepa JK, Sun W, Bruder JM, Wierman ME: Comparison of GnRH promoter activity in placental

and hypothalamic cells. The 71st Annual Meeting of the Endocrine Society 1991; 1730.

22

22. Bruder JM, Krebs WD, Wierman ME: The role of protein kinase C in the regulation of gonadotropin releasing hormone (GnRH) gene expression. Clinical Res 1992; 85A.

23. Bruder JM, Krebs WD, Wierman ME: Activation of protein kinase C inhibits gonadotropin

releasing hormone (GnRH) gene expression. The Endocrine Society 1991; 826. 24. Kepa JK, Neeley CI, Wierman ME: Estrogen receptor mediated regulation of gonadotropin

releasing hormone (GnRH) promoter activity in hypothalamic cells. The Keystone Symposia, Steroid/Thyroid Receptor Gene Super Family, February 1992.

25. Kepa JK, Neeley CI, Wierman ME: Estrogen receptor mediated regulation of gonadotropin

releasing hormone (GnRH) promoter activity in hypothalamic cells. The 72nd Annual Meeting of the Endocrine Society 1992; 189.

26. Kepa JK, Boen EA, Wierman ME: Localization of an androgen responsive cis-acting DNA

element in the rat GnRH gene. The 73rd Annual Meeting of the Endocrine Society 1993; 1984. 27. Wierman ME: Regulation of gonadotropin releasing hormone (GnRH) gene expression. The

73rd Annual Meeting of the Endocrine Society 1993; 28F. 28. Bruder JM, Wierman ME: Protein kinase C (PKC) inhibition of rat GnRH promoter activity is

associated with an increase in c-Fos and c-Jun mRNA and mimicked by overexpression of c-Fos and c-Jun. The 73rd Annual Meeting of the Endocrine Society 1993; 1985.

29. Nilaver G, Neeley CI, Wierman ME, Nagalla S, Spindel E, Ojeda SR: Identification of a

SCIP/Tst1-like POU domain nuclear transcription factor in GT1-7 cells: Overexpression suppresses rat GnRH promoter activity. The 73rd Annual Meeting of the Endocrine Society 1993; 1552.

30. Faber KA, Bruder JM, Awoniyi CA, Wierman ME: Neonatal diethylstilbestrol (DES) exposure

effects on serum gonadotropin levels and pituitary gonadotropin subunit messenger RNA levels in the castrated pubertal male rat. American Fertility Society 1993.

31. Dunkelberg J, Debray D, Wierman ME, Brown WR: Chronic ethanol feeding of male rats

decreases hepatic asialoglycoprotein receptor (ASGPR) gene expression. American Gastroenterological Association 1993.

32. Bruder JM, Samuels MH, Bremner W, Ridgway EC, Wierman ME: Use of a GnRH agonist to

investigate the mechanism of childhood hypothyroidism-induced macroorchidism and to augment ultimate adult stature. WSCI 1993.

33. Mahoney J, Bruder JM, Balanoff A, Draznin B, Wierman ME: Effectiveness of laboratory

assessment of the pituitary-gonadal axis in patients with impotence. WSCI 1993. 34. Kepa JK, Jacobsen BM, Boen EA, Takimoto G, Edwards D, Wierman ME: Two sites in the

proximal rat GnRH (rGnRH) promoter mediate negative regulation by progesterone. The 74th

Annual Endocrine Society 1994. 35. Bruder JM, Samuels MH, Bremner WJ, Ridgway EC, Wierman ME: Hypothyroidism-induced

macroorchidism: Use of a GnRH agonist to understand its mechanism and to augment adult stature. The 74th Annual Meeting of the Endocrine Society 1994.

23

36. Faber KA, Awoniyi CA, Hurst BS, Schlaff WD, Wierman ME: Neonatal exposure to the naturally- occurring phytoestrogen genistein induces gonadal injury and alters normal patterns of gonadotropin gene expression in female but not in male rats. The American Fertility Society 1994.

37. Wierman ME, Jacobsen B, Kepa J, Radovick S, Chou J, Bruder J: Tissue specific expression of

the GnRH gene in SPA-209 human placental cells. WSCI 1995. 38. Kepa JK, Jacobsen BM, Bruder JM, Wierman ME: Brain-4 (Brn-4) POU protein activates rat

GnRH promoter activity in GT1-7 neuronal cells and blocks repression by SCIP. The 75th Annual Meeting of the Endocrine Society 1995.

39. Wierman ME, Jacobsen BM, Kepa JK, Latzka MD, Radovick S, Chou J: Placental specific

expression of the GnRH gene in SPA-209 human placental cells. The 75th Annual Meeting of the Endocrine Society 1995.

40. Fang ZQ, James RA, Gordon DF, Spaulding AJ, Wierman ME: Differentially expressed genes in

two GnRH expressing neuronal cell lines: Gn-10 and GT1-7. The 78th Annual Meeting of the Endocrine Society 1996.

41. Wierman ME, Kepa JK, Spaulding AJ, Radovick S, Fang Z: Species specific differences in the

promoter organization of the gonadotropin releasing hormone (GnRH) gene: rat and human. Society for the Study of Reproduction 1996.

42. Stabler SP, Sumner AE, Sterling FH, Wierman ME, Allen RH: Cobalamin (Cbl) deficiency and

hyperhomostinemia in thyroid disease. American Society of Hematology 1996. 43. Xiong X, Spaulding A, Dunn K, Wierman ME: Role of a SRY box protein in SCIP/Tst-1/Oct-6

repression of neuronal Gonadotropin releasing hormone (GnRH) gene expression. WSCI , Carmel, CA, 1997.

44. Xiong X, Dunn K, Zhao C, Wierman ME: SCIP/Tst-1/Oct-6 repression of neuronal GnRH gene

expression: role of a SRY box (Sox) protein. The 79th Annual Meeting of the Endocrine Society, June 1997.

45. Xiong X, Dunn K, Zhao C, Wierman ME: Cross-talk of Sox-2 with POU proteins to control

neuronal GnRH expression. Society for Neuroscience 1997. 46. Wierman ME, Schneider K, Meintzer MK, Zeng C, Xiong, Heidenreich KA: Growth arrest specific

gene 6 (Gas6)/adhesion related kinase (Ark) signaling in GnRH neurons: Control of GnRH transcription and protection from apoptosis. WSCI, Carmel CA, Feb 1998.

47. Xiong X, Zeng C, Schneider K, Meintzer MK, Heidenreich KA, Wierman ME: Regulation of

neuronal GnRH transcription and apoptosis by growth arrest specific gene 6 (Gas6)/adhesion related kinase (Ark) signaling. The 80th Annual meeting of the Endocrine Society, San Diego, CA, 1998.

48. Wierman ME, Xu M, Zeng C, Allen MP: POU domain proteins in GT1-7 neuronal cells:

Activation of the gonadotropin releasing hormone (GnRH) promoter by OCT3/4. WSCI 1999. 49. Allen MP, Xu M, Zeng C, Naya F, Olson EN, Wierman ME: Adhesion related kinase (Ark)

repression of GnRH gene expression: The role of MEF-2 transcription factors. The 81st Annual Meeting of the Endocrine Society, Minneapolis, June 1999.

24

50. Imanishi Y, Palanisamy N, Tahara H, Vickery A, Cryns VL, Gaz RD, Shoback D, Clark O, Monchik J, Wierman ME, Hollenberg A, Tojo K, Chaganti RSK, Arnold A: Molecular pathogenetic analysis of parathyroid carcinoma. ASBMR 1999.

51. Wierman ME, Allen MP, Zang C, Xu M, Dowell C: Developmental expression of the GnRH gene.

The 5th international conference on the Control of the Onset of Puberty, Liege, Belgium, 1999. 52. Wierman ME: Factors regulating GnRH neurons, symposia. The 82nd Annual Meeting of the

Endocrine Society 2000, Toronto Canada, June 2000. 53. Allen MP, Xu M, Dowell C, Edwards DP, Wilson EM, Wierman ME: Protein-protein interactions

at non-consensus negative androgen response elements mediate androgen receptor repression of GnRH promoter activity in neuronal cells. The 82nd Annual Meeting of the Endocrine Society, Toronto, Canada, June 2000.

54. Allen MP, Xu M, Zeng C, Wierman ME: Adhesion related kinase (Ark) repression of GnRH

transcription occurs via the ERK1,2 pathway and a novel homeoprotein/MEF-2 interaction. The 82nd Annual Meeting of the Endocrine Society, Toronto, Canada, June 2000.

55. Allen MP, Schwartz C, Xu M, Wierman ME: Growth arrest specific gene 6 (Gas6)/Adhesion

related kinase (Ark) signaling promotes GnRH neuronal migration. The Society for Neuroscience, New Orleans, 2000.

56. Allen MP, Linseman DA, Xu M, Heidenreich KA, Wierman ME: Cytoskeletal remodeling and

migration of immortalized gonadotropin releasing hormone (GnRH) neurons is mediated by an adhesion related kinase (Ark)- RAC- P38 MAPK signaling pathway. The 83rd Annual Meeting of the Endocrine Society, Denver CO, June 2001.

57. Pawlowski JE, Allen MP, Ertel JR, Xu M, Lent D, Wierman ME: Liganded androgen receptor

induces nuclear translocation of β-catenin in GT1-7 gonadotropin releasing hormone (GnRH) neuronal cells. The 83rd Annual Meeting of the Endocrine Society, Denver, Co, June 2001.

58. Pawlowski JE, Allen MP, Xu M, Ertel JR, Tyler KL, Wierman ME: The GnRH promoter is

differentially regulated by the homeodomain proteins, Otx-2, SCIP and Brn-4 in migratory (NLT) versus postmigratory (GT1-7) GnRH neuronal cell lines. Society for Neuroscience, 2001.

59. Allen MP, Linseman DA, Xu M, Heidenreich KA, Wierman ME: PI3K couples the adhesion

related kinase (Ark) receptor to a Rac/p38 MAPK dependent migratory pathway in GnRH neurons. Society for Neuroscience, 2001.

60. Hubbard L, Xu M, Ertel JR, Allen MP, Pawlowski JE, Wierman ME: The role of sine oculis (Six)

family homeoproteins in gonadotropin releasing hormone (GnRH) gene expression. Western Society for Clinical Investigation, Carmel, CA, 2002.

61. Pawlowski JE, Ertel JR, Allen MP, Xu M, Wilson EM, Wierman ME: Androgen receptor

interaction with beta-catenin in GnRH neuronal cells: nuclear co-localization and modulation of transcription. Keystone Symposia: Nuclear Receptor Superfamily, Snowbird, UT, 2002.

62. Pawlowski JE, Ertel JR, Xu M, Allen MP, Wierman ME: Liganded androgen receptor inhibits otx-

2 stimulation of the gonadotropin releasing hormone (GnRH) promoter in GnRH neuronal cells. 84th Annual Meeting of The Endocrine Society, San Francisco, CA, 2002.

25

63. Pawlowski JE, Xu M, Ertel JR, Ford HL, Hubbard L, Wierman ME: Regulation of gonadotropin releasing hormone (GnRH) expression by members of the sine oculis (Six) family of transcription factors. 85th Annual Meeting of The Endocrine Society, Philadelphia, PA, June 2003.

64. Pawlowski JE, Ertel JR, Xu M, Wierman ME: Roles of SRY-box (Sox) proteins in neuronal

gonadotropin releasing hormone (GnRH) expression. 85th Annual Meeting of the Endocrine Society, Philadelphia, PA, June 2003.

65. Nielsen-Preiss S, Xu M, Pawlowski J, Ertel J, Gillette J, Varnum B, Wierman ME: Dissecting the

differential roles of axl-family tyrosine kinase receptors in GnRH neuronal cells. The 86th Annual Meeting of the Endocrine Society, New Orleans, LA, June 2004.

66. Nielsen-Preiss SM, Xu M, Gillette J, Haughian J, Wierman ME: Lipid raft modulation of Gas6

induced axl signaling in GnRH neurons. Society for Neuroscience. San Diego, CA, November 2004.

67. Li HY, McDermott DS, Lotts MM, Ertel JR, Xu M, Lillehei KO, DeMasters BK, Nielsen-Preiss SM,

Pawlowski JE, Wierman ME: Differential expression of bone morphogenic protein -5, promyelocytic leukemia zinc finger and members of the GATA family in gonadotropinomas. WSCI, Carmel, CA February, 2005.

68. Shorts-Cary L, Ertel J, Li H, Xu M, DeMasters BK, Lillehei K, Nielson-Preiss S, Wierman ME:

Identification of novel candidates for pituitary tumorigenesis. 9th International Pituitary Congress, San Diego, CA June 2005.

69. Wierman ME: Gonadotropin releasing hormone (GnRH) neuron biology: Through the looking

glass. NICHD Symposia on the GnRH Neuron, November, 2005. 70. Shorts-Cary L, Ertel J, Ariola-Tirelli R, Xu M, DeMasters BK, Lillehei K, Nielsen-Preiss S,

Wierman ME: Identification of bone morphogenic protein and retinoic acid inducible neural- specific protein (BRINP-3) as a novel candidate in pituitary gonadotropinomas. UCDSC Dept of Med Research Day, November, 2005.

71. Ronnekleiv-Kelly S, Ariola-Tirella R, Xu M, Lillehei KO, DeMasters BK, Shorts-Cary L, Wierman

ME: Epidermal growth factor receptor substrate 8(Eps8) is overexpressed in gonadotroprinomas. WSCI, Carmel CA, February, 2006.

72. Shorts-Cary L, Xu M, Li H, Ertel J, DeMasters BK, Lillehei K, Nielsen-Preiss S, Wierman ME:

Identification of bone morphogenetic protein and retinoic acid inducible neural-specific protein-3 (BRINP3) as a novel candidate in human pituitary gonadotropinomas. The Endocrine Society, Boston, MA, June 2006.

73. Xu M, Ronnekiev-Kelly S, Shorts-Cary L, Ertel J, DeMasters BK, Lillehei K, Nielsen-Priess S,

Wierman ME: Epidermal growth factor substrate (Eps8) is up regulated and sprouty-4 (Spry4) is down regulated in human pituitary tumors: a mode of growth factor amplification? The Endocrine Society, Boston, MA, June 2006.

74. Navratil AM, Knoll JG, Nielsen-Preiss S, Garber SK, Wierman ME, Tobet SA, Clay CM: GnRH

engagement of the actin cytoskeleton leads to migration and dynamic cellular movements in the anterior pituitary gland. The Endocrine Society, Boston MA, June 2006.

26

75. Xu M, Shorts-Cary L, Moriarty M, Bliesner B, Summers B, Schall TJ, Tobet S, Wierman ME: Differential expression of chemokines and chemokine receptors in GnRH neuronal cells: Role in migration and/or survival? The Endocrine Society, Toronto CA, June 2007.

76. Pierce AM, Bliesner BS, Xu M, Tobet S, Lemke G, Wierman ME: Axl and Tyro3 regulate GnRH

neuron migration and modulate female reproductive function. The Endocrine Society, San Francisco, CA 2008.

77. Knox AJ, McNamara SA, Xu M, Wierman ME: Analysis of reprimo expression and function in

pituitary tumors. The WSCI Carmel meetings, Carmel CA, 2009. 78. Tobet SA, Wierman ME, Veeramachaneni DNR, Schwarting GE: GnRH neuron migration: A long

and dangerous road? The Japanese Endocrine Society, Kyoto Japan, 2009. 79. Knox AJ, Xu M, Plummer L, Slavov D, Taylor D, Pitteloud N, Crowley WF, Wierman ME.

Analysis of mutations in Axl and Tyro3 in probands with Kallmann’s syndrome and idiopathic hypogonadotropic hypogonadism. The Endocrine Society, Washington DC, 2009.

80. Rothman MS, Carlson NE, Xu M, Wang C, Swerdloff R, Lee P, Goh V, Ridgway EC, Wierman

ME. Re-examination of testosterone, dihydrotestosterone and estradiol levels measured by liquid chromatography tandem mass spectrometry across the menstrual cycle, in postmenopausal women and men across the lifespan. The Endocrine Society, Washington DC, 2009.

81. Knox AJ, Xu M, Edwards M, Wierman ME. Inhibition of Reprimo in pituitary tumors.

InternationalPituitary Society Congress, Washington, DC June 2009. 82. Kisseljack-Vassiliatis K, Howard D, Kerr J and Wierman ME. Effectiveness of etomidate in a

patient with ectopic ACTH syndrome presenting with disseminated Nocardiosis. The Endocrine Society, San Diego, CA, June 2010.

83. Fretwell DL, Knox AJ, Xu M,Wierman ME, Lillehei KO, Kleinschmeidt-DeMasters B,Kerr JM.

MicroRNA-200c is Down-Regulated in Sparsely-Granulated Growth Hormone Pituitary Tumors and Regulates ZEB1 expression in GH-derived cells. The Endocrine Society, San Diego, CA, June 2010.

84. Wierman ME, Pierce A, Bliesner B, Xu M, Bliss S, Roberson M. Selective Deletion of ERK1,2 in

GnRH neurons does not alter neuronal survival, targeting or reproductive function. The Endocrine Society, San Diego, CA, June 2010.

85. Knox A, Edwards M, Xu M, Geraci M, Kleinschmidt-DeMasters B, Lillehei K and Wierman ME.

Devleoping Biomarkers of Pituitary Tumor Progression and Recurrence. The Endocrine Society, San Diego, CA, June 2010.

86. Knox A, Xu M, Edwards M, Kleinschmidt-DeMasters B, Lillehei K, Geraci M and Wierman ME.

Assessing genomic deregulation in human pituitary tumors to identify markers of disease progression. The Endocrine Society, San Diego, CA, June 2010.

87. Meditz A, Moreau K, Gozansky W, Kelsey M, Kohrt W, Wierman ME Connick L. Healthy

Postmeonpausal Women have higher percentages of CCR5+ Cervial CD4+T cells compared to Premenopausal Women: implications for HIV transmission. Conference on Retroviruses and Opportunistic Infections (CRO1 2011), Boston, MA.

27

88. Knox AJ,Edwards MG, Kiseljak-Vassiliades K, Xu M, Michaelis KA, Kleinschmidt-Demasters B,Lillehei KO and Wierman ME. Gene amplification and upregulation of mammalian STE20-like protein kinase 4 (MST4) reveal a novel candidate gene in human pituitary tumorigenesis. The Endocrine Society, Boston, MA, June 2011.

89. Kiseljak-Vassiliades K, Xu M, Knox AJ, Edwards MG, Michaelis KA, Kleinschmidt-Demasters B,

Lillehei KO, Geraci M and Wierman ME. Pro-Survival and Tumorigenicity of LAG1 Homolog Ceramide Synthase 6 (LASS6) in Gonadotrope Pituitary Tumors. The Endocrine Society, Boston, MA, June 2011.

90. Salian Mehta S, Xu M, Schaller M and Wierman ME. Axl and Met: Crosstalk of Tyrosine Kinase

Receptor Signaling in GnRH Neurons. The Endocrine Society, Boston, MA, June 2011. 91. Michaelis K, Knox AJ, Xu M, Kiseljak-Vassiliades K, Edwards MG, Kleinschmidt-DeMasters BK,

Lillehei K, Geraci M, and Wierman ME. Repression of GADD45β in Human Gonadotrope Pituitary Tumors: Role in Proliferation, Survival and Tumorigenesis. The Endocrine Society, Boston, MA June 2011.

92. Thompson IB, Tang D, Xu S, Wierman ME, Laws ER, Shi Y, Carroll RS and Kaiser UB.

Upregulation of Histone Modifying Enzymes: Implications in the Pathogenesis of Human Pituitary Adenomas. The Endocrine Society, Boston, MA, June 2011.

93. Mehta S, Xu M, McKinsey T, Wierman ME. Deciphering the role of histone deacetylases in

GnRH neuronal development. Society for Neuroscience, Washington, DC, Nov 2011. 94. Wierman ME. Fertility options in patients with hypopituitarism. International Congress of

Endocrinology, Florence Italy, May 2012. 95. Kiseljak-Vassiliades K, Shibana S, Xu M, Kleinschmidt-Demasters B, Lillehei K, Kerr J,

Wierman ME. Clinical and Genomic Profiling of Growth Hormone Tumor Subtypes to Identify Mechanisms of Disease Pathogenesis, Aggressiveness, and Response to Therapy. The Endocrine Society, Houston Tx, June 2012.

96. Salian-Mehta S, Xu M, Busta E, Horn T, Mckinsey T and Wierman ME. Epigenetic control of

GnRH neuron development: role of histone deacetylase 9 (HDAC9). The Endocrine Society, Houston, TX, June 2012 .

97. Salian-Mehta S, Xu M, Nash C, Stratton MS, McKinsey T, Menick DR, Tobet S, Wierman ME.

Understanding Histone Deacetylase 9 (HDAC9) Function in GnRH Neuron Biology. The Endocrine Society, San Francisco, CA, June 2013.

98. Wierman ME, Xu M, Tian M, Kiseljak-Vassiliades K, Knox AJ,Edwards M, Kleinschmidt-

Demasters B, Geraci M, Lillehei K. Copy Number Amplification and Overexpression of Mammalian Sterile 20-Like Kinase 4 (MST4) in Pituitary Tumors: a Novel Therapeutic Target. The Endocrine Society, San Francisco, CA, June 2013.

99. Wierman ME. Oxidatative Stress and Hypoxia-Induced Signaling Pathways in Pituitary

Tumorigenesis (symposia). The Endocrine Society, San Francisco, CA, June 2013. 100. Kiseljak-Vassiliades K, Carlson NE, Borges MT, Kleinschmidt-DeMasters BK, Kerr JM and

Wierman ME. Histological subtypingof Growth Hormone Pituitary Tumors Predicts Response to Surgical and Medical Therapy in Acromegaly. The International Congress of Endocrinology, Chicago Ill, June 2014.

28

101. Xiong W, Xu M, Kiseljak-Vassiliades K, Colgan SP, Brodsky KS, Elzschig HK, Kleinschmidt- Demasters KK, Lillehei KO and Wierman ME. Mechanism of Mammalian STE20-like Kinase 4 (MST4) to Promote Pituitary Tumor Cell Survial and Proliferation under Hypoxic Conditions. The International Congress of Endocrinology, Chicago,Il June 2014.

102. Salina-Mehta S, McKinsey TA, Tobet S and Wierman ME. Novel Interaction of Class IIb Histone

Deacetylase (HDAC)6 with Class IIa HDAC 9 Controls GnRH Neuronal cell Survival and Migration. The International Congress of Endocrinology, Chicago, Il, June 2014.

103. Meditz AL, Mawhinney S, Moreau K, Melander K, Folkvord J, Kohrt W, Wierman M, Connick E

Estrogen Replacement in Postmenopausal Women Reduces % CCCR5+ CD4+ T cells. CROI San Francisco, CA March 2015.

104. Kiseljak-Vassiliades K,Gowan K, Xu M, Mills T, Kleinschmidt-DeMasters BK, Lillehei KO,

Jones K and Wierman ME. Genomic and Genetic Analysis of Growth Hormone Pituitary Tumor Subtypes. The Endocrine Society, San Diego CA, March 2015.

105 Guiahi M, Waldbaum AS, Schecter CA, Duke DM, Wierman ME, Robinson WA, Duke RC,

Emlen W, Santoro NF. Can Human Recombinatn Granulocyt-Colony Stimulating Factor Improve Menopausal Hot Flashes? Results of a Pilot Study. Society of Reproductive Investigation, San Francisco, CA April, 2015.

106. Xiong W, Matheson CM, Backos DS, Xu M, Kiseljak-Vassiliades, Salian-Mehta S, Reigan P,

Wierman ME. Identification of a Mammalian Sterile-20 like Kinase 4 (MST4) Inhibitor to Target Pituitary Tumorigenesis. AACR , Philadelphia, PA, April 2015.

107. Guiahi M, Waldbaum AS,Schecter CA, Duke DM, Wierman ME, Robinson WA, Duke RC,

Emlen W, Santoro N. Can Human Recombinant Granulocyte-Colony Stimulating Factor Improve Menopausal Hot Flashes?: Results from a Pilot Study, Society of Reproductive Investigation, San Francisco, CA April 2015.

108. Ripley D et al Testosterone replacement in hypogonadal men following Traumatic Brin Injury:

results from a double-blind, placebo controlled pilot study. AAPM&R Boston, MA, 2015.

109. Wierman ME et al, Natural history of neuroendocrine dysfunction after traumatic brain injury during inpatient rehabilitation. AAPM&R Boston MA, 2015.